Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction, with guests from GSK, IQVIA, Exelixis and DataHow.
The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patient safety?
Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction.
This is part two of a discussion focused upon data bias, accuracy, access and the future of AI in drug development.
Guests
Paul Agapow, Director of Innovation, Data Science and Strategy, GlaxoSmithKline
Mike King, Senior Director of Product and Strategy, IQVIA
Nindhana Paranthaman, Executive Medical Director, Exelixis
Moritz von Stosch, Chief Information Officer, DataHow
Host
Lori Ellis, Head of Insights, BioSpace
Lori Ellis is the head of insights at BioSpace, providing industry analysis as well as custom content for BioSpace clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at lori.ellis@biospace.com. Follow her on LinkedIn.
